Results: 39 pts (male 10, female 29; median age 58 years; 11BRCA mutation carriers) were treated... Conclusions: MK-4827 is well tolerated, blocks PARP and haspromising
antitumor activity in both BRCA-deficient and sporadiccancers.
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.